

**Listing of Claims:**

1-74. (cancelled)

75. (Newly presented) A topical method of decreasing phagocytosis or ICAM-1 expression in a patient having one or more of the conditions consisting of pulmonary emphysema, immunological lung disorders, periodontal disease, atherosclerotic plaques, Mid-dermal elastosis, pigmentation disorders, psoriasis, eczema and Acne vulgaris, comprising applying topically to an affected organ of said patient a therapeutically phagocytosis- or ICAM-1 decreasing effective amount of composition containing active trypsin inhibitory activity comprising a non-denatured soy product having active trypsin inhibitory activity.

76. (Newly presented) The method of claim 75, wherein the composition inhibits the PAR-2 pathway.

77. (Newly presented) The method of claim 75, wherein the composition is selected from the group consisting of a soybean derivative and a serine protease inhibitor.

78. (previously presented) The method of claim 77, wherein the composition is selected from the group consisting of soybean milk containing soybean trypsin inhibitor.

79. (Newly presented) The method of claim 75, wherein the affected organ contains PAR-2-expressing cells.

80. (Newly presented) The method of claim 79, wherein the affected organ contains cells selected from the group consisting of a keratinocyte, a fibroblast, and a professional phagocytic cell.

81. (Newly presented) The method of claim 80, wherein the affected organ contains keratinocytes.

82. (Newly presented) The method of claim 80, wherein the affected organ contains fibroblasts.

83. (Newly presented) The method of claim 80, wherein the affected organ contains professional phagocytic cell.

84. (Newly presented) The method of claim 75, wherein the affected organ is a human organ.

85. (Newly presented) The method of claim 75 wherein the non-denatured soy product is selected from the group consisting of: soybean milk containing STI and soybean paste containing STI.